Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.33 USD
+0.51 (5.78%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $9.34 +0.01 (0.11%) 5:22 PM ET
1-Strong Buy of 5 1
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TBPH 9.33 +0.51(5.78%)
Will TBPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Here's Why You May Invest in Theravance (TBPH) Stock Now
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Other News for TBPH
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Sidoti Events, LLC's Virtual June Small-Cap Conference
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Theravance Biopharma (TBPH) Receives a Hold from TD Cowen
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)